Dave Coulier, known for his role on Full House, told Good Morning America this week that he is now in remission after treatment for two separate cancers — a recent tongue tumor found during follow-up care for an earlier lymphoma diagnosis. His update underscores the importance of routine scans and quick action after suspicious findings.
From lymphoma to tongue cancer: a swift, unexpected turn
In November 2024 Coulier publicly disclosed a diagnosis of stage 3 non-Hodgkin lymphoma. During a subsequent checkup, a PET scan flagged an abnormality in his throat. Doctors performed a robotic-assisted procedure that removed part of his tongue for biopsy, which led to a second diagnosis: p16 squamous carcinoma at the base of the tongue.
The two cancers are unrelated, Coulier said, and after surgery and follow-up treatment he now reports both illnesses are in remission. He described the tongue operation as painful and invasive, and has been candid about the emotional and physical toll of back-to-back cancer care.
Support system and small moments that mattered
Coulier credited his wife, Melissa Bring, and friends from his Full House circle for steadying him. He recounted a visit from John Stamos — a brief, lighthearted interlude that helped break the tension — and even joked about sharing an awkward bout of COVID while Stamos stayed with them, which turned into an unexpectedly silly memory.
- Diagnosis timeline: Stage 3 non-Hodgkin lymphoma announced Nov. 2024; tongue carcinoma identified during a later PET scan.
- Treatment steps: Robotic surgery to remove part of the tongue for biopsy, followed by appropriate oncological care.
- Current status: Coulier says both cancers are in remission.
- Takeaway: He urges people to prioritize routine exams and screenings — from prostate checks to mammograms — because early detection can be decisive.
Coulier told the program he never wanted to be a “poster boy” for cancer awareness, but he hopes sharing his experience motivates others to see a physician sooner rather than later. He emphasized that even in remission, the experience leaves a lasting impression — cancer, he says, remains “in the rear-view mirror.”
Why this matters now: Coulier’s case is a reminder that follow-up imaging after cancer treatment can reveal unrelated health issues, and that prompt investigation of new findings can change outcomes. For readers, the practical consequence is clear — stay current with recommended screenings and speak up about unusual symptoms.
